PT-141 (Bremelanotide)

What is PT-141 (Bremelanotide)?

PT-141, known generically as Bremelanotide, is a synthetic melanocortin peptide derived from Melanotan II. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the only centrally-acting sexual health peptide with regulatory approval.

Unlike all previous sexual health compounds (PDE5 inhibitors like sildenafil, which act on the vascular system), PT-141 works through the central nervous system — specifically through melanocortin receptor activation in the hypothalamus — to enhance sexual arousal and desire at the neurological level.

Mechanism of Action

MC3R and MC4R Agonism

PT-141 selectively activates melanocortin 3 and 4 receptors (MC3R and MC4R) in the brain's limbic and hypothalamic regions. These receptors are involved in regulating sexual behavior, arousal, and motivation. MC4R activation in the paraventricular nucleus of the hypothalamus specifically enhances male erectile response through neural pathways — distinct from the vasodilatory mechanism of PDE5 inhibitors.

Central vs. Peripheral Mechanism

This central mechanism is PT-141's defining characteristic. It addresses the neurological component of sexual dysfunction — desire and arousal — rather than simply improving vascular response. Research suggests this distinction makes PT-141 effective in cases where PDE5 inhibitors fail, because it addresses a different dimension of sexual function.

Non-Cardiovascular

By acting centrally rather than on vascular tissue, PT-141 avoids the cardiovascular effects (blood pressure changes) that limit PDE5 inhibitor use in certain populations.

Key Research Findings

Female HSDD

The pivotal trials that led to FDA approval demonstrated significant improvements in sexual desire, arousal, and satisfying sexual events compared to placebo in women with HSDD — validating the central arousal mechanism.

Male Erectile Response

Studies in men with erectile dysfunction showed PT-141 produced erections through a central pathway — with effects complementary to rather than competitive with PDE5 inhibitors. Some subjects non-responsive to PDE5 inhibitors responded to PT-141.

Both Male and Female Applications

Unlike Vyleesi's female-specific approval, research protocols examine PT-141 in both sexes — recognizing that MC3R/MC4R signaling in sexual arousal pathways is relevant to all genders.

*For research use only. Not for human consumption.*